LPU A.I CyberSecurity Scoring
04/03/2026
Access Monitoring Plan
Access Monitoring Plan
No incidents recorded for LEO Pharma UK/IE in 2026.
No incidents recorded for LEO Pharma UK/IE in 2026.
No incidents recorded for LEO Pharma UK/IE in 2026.
Pharmaceutical Manufacturing
We’re not your typical healthcare company. In a modern world of quick fixes, we focus on solutions to defeat serious chronic disease and create long-term health. We seek out new ideas and put people first as we push the boundaries of science, make healthcare more accessible, and work to treat, prevent, and even cure diseases that affect millions of lives. Founded in Denmark in 1923, today we employ more than 68,800 people in 80 offices around the world – all united by our bold purpose to drive change to defeat serious chronic diseases. Want to learn more? Visit www.novonordisk.com. This page isn’t intended for discussions about products. As such, postings or comments that contain product discussions may be removed. This page is for discussions about Novo Nordisk and its subsidiaries and the initiatives and projects we are involved in. While we welcome everyone to make comments, we reserve the right to block and remove those that are off-topic, abusive or intended to spam. Any questions specific to products should be made to your healthcare professional. If you wish to file an adverse drug reaction please contact Novo Nordisk’s office in the country you live in: https://www.novonordisk.com/contact-us/find-local-information.html For other customer complaints, please contact us here: https://www.novonordisk.com/contact-us.html Please keep in mind that Novo Nordisk A/S and its subsidiaries work within a highly regulated industry. Therefore, comments that pertain to legal matters or regulatory issues may be removed. Comments contained on this site come from members of the public, and do not necessarily reflect the views of Novo Nordisk A/S. Novo Nordisk A/S does not endorse or approve any content added by other LinkedIn users. Learn more about our privacy disclaimer and community guidelines here: https://www.novonordisk.com/data-privacy-and-user-rights/social-media-privacy-disclaimer.html
At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.merck.com. This site is intended for residents of the United States and Canada and their territories only. FLS: http://merck.us/3TKXNuZ
Novartis is an innovative medicines company. Every day, working to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide. Find out more at https://www.novartis.com See our community guidelines: https://go.novartis.social/3Nboxki
We're a medicine company turning science into healing to make life better for people around the world. It all started nearly 150 years ago with a clear vision from founder Colonel Eli Lilly: "Take what you find here and make it better and better." Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing science to solve some of the world's most significant health challenges. General Information and Guidelines: When you engage with us on LinkedIn, you're agreeing to these Community Guidelines: https://e.lilly/guidelines. If you have questions about a Lilly medicine, contact The Lilly Answers Center at 1-800-Lilly-Rx (1-800-545-5979) Monday through Friday, excluding company holidays.
The Zydus Group with an overarching purpose of empowering people with freedom to live healthier and more fulfilled lives, is an innovative, global life-sciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group employs over 27000 people worldwide and is driven by its mission to unlock new possibilities in life-sciences through quality healthcare solutions that impact lives. The group aspires to transform lives through pathbreaking discoveries.
At Bristol Myers Squibb, we work every day to transform patients’ lives through science. That work inspires some of the most interesting, meaningful, and life-changing careers you’ll experience. Join us and pursue innovative ideas alongside some of the brightest minds in biopharma, collaborating with a team rich in diversity of experiences, and perspectives. We have built a sustainable pipeline of potential therapies and are leveraging translational medicine and data analytics to understand how we can deliver the right medicine to the right patient, at the right time, to achieve the best outcome. Whether in a scientific, business or supporting function, a career at BMS means you’ll be inspired every day to grow and thrive through opportunities that are uncommon in scale and scope. Here, you’ll be on the cutting edge of powerful innovation in oncology, hematology, immunology, cardiovascular disease, and fibrosis, with colleagues united in the mission to help patients. Through the Bristol Myers Squibb Foundation, we also promote health equity and seek to improve health outcomes of populations disproportionately affected by serious diseases and conditions. Our mission is to give new hope to help patients prevail over serious disease – it drives everything we do. Review our Social Media Community Guidelines at: https://www.bms.com/social-media-community-guidelines.html
Astellas is a global life sciences company committed to turning innovative science into VALUE for patients. We provide transformative therapies in disease areas that include oncology, ophthalmology, urology, immunology and women's health. Through our research and development programs, we are pioneering new healthcare solutions for diseases with high unmet medical need. Visit our Global Astellas LinkedIn Community Guidelines to learn more about interacting with this page: https://www.astellas.com/en/global-linkedin-community-guidelines
Parexel is a leading global clinical research organization (CRO) providing insights-driven Clinical and Consulting solutions to the world’s life sciences industry. Leveraging deep local knowledge and a global breadth of clinical, regulatory and therapeutic expertise, our 24,000+ professionals worldwide work in partnership with biopharmaceutical leaders, emerging innovators and sites to design and deliver clinical trials with patients in mind — broadening access and making clinical research a care option for anyone, anywhere. Our proven track record spans 40+ years and drives us forward, advancing clinical research in healthcare’s most complex areas while harnessing innovation to drive efficiencies across every phase of the clinical development process. Our insights-driven approach, proven delivery and trusted execution are accelerating the delivery of life-changing treatments to patients — With Heart.™ We continue to earn recognition industrywide, including the 2025 Scrip Award for “Best Contract Research Organization – Full-Service Provider,” 2024 Fierce Biotech CRO Award for "Innovative Approaches to Patient-Centric Research" and the 2024 and 2023 Society for Clinical Research Sites (SCRS) Eagle Award. Community Guidelines Because Parexel’s social media channels are open to the general public and employees, we are not responsible for views expressed other than our own. However, we do not tolerate posts that are: • Abusive, harassing or threatening to others. • Defamatory, offensive, obscene, vulgar or depicting violence. • Hateful targeting by race/ethnicity, age, color, creed, religion, gender, sexual preference or orientation, nationality or political beliefs. • Sexually explicit or pornographic. • Fraudulent, deceptive, libelous, misleading or unlawful. • Referencing criminal or illegal activity. • Spamming. We reserve the right to remove comments that do not adhere to our guidelines and report users who violate the rules of our page.
Championing the missions that matter™. Catalent, Inc. is a leading global contract development and manufacturing organization (CDMO) and trusted partner to pharma, biotech, and consumer health companies worldwide. We put patients first in everything we do, helping people live better and healthier lives through every product we help develop, manufacture and deliver. With over 1,000 active development programs at any given time, we launch over 100 new products and line extensions annually. Catalent has supported half of all FDA approvals over the past decade, and our teams working at over 40 global sites help us produce over 60 billion doses every year. Our strength lies in our people: teams across our more than 40 sites and thousands of passionate scientists and technicians who bring expertise in development sciences, delivery technologies, and multi-modality manufacturing. What unites us is our commitment to championing our partners’ missions as our own, anticipating customer needs, solving complex challenges and ultimately making a difference in the lives of patients across the globe. At Catalent, you will be able to directly have an impact, solving problems and ensuring excellence for our customers. Our focus on delivering meaningful outcomes alongside our customers means your work directly impacts millions of people around the world. Join us in championing the missions that matter. Catalent is headquartered in Tampa, Florida, with over 40 global sites. Visit www.catalent.com to learn more.
Latest updates, reports, and threat intel affecting the global network.
The National Institute for Health and Care Excellence (NICE) has recommended the first-and-only topical treatment for adults in the United...
Leo Pharma has gained marketing authorisation from the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) for its topical pan-Janus kinase (JAK)...
docker-socket-proxy fails to properly gate read endpoints in the /containers Docker API namespace when the CONTAINERS environment variable is set. Attackers can use GET requests to /containers/{id}/archive, /containers/{id}/export, /containers/{id}/logs, and /containers/{id}/top to read arbitrary files and download entire container filesystems as tar archives.
A vulnerability has been found in Systerel S2OPC up to 1.7.3. Impacted is the function SOPC_NodeMgtHelperInternal_AddVariableNodeAttributes of the file src/ClientServer/address_space/internal/sopc_node_mgt_helper_internal.c of the component AddNodes Service. The manipulation of the argument UserAccessLevel leads to out-of-bounds read. It is possible to initiate the attack remotely. A high degree of complexity is needed for the attack. The exploitability is considered difficult. The exploit has been disclosed to the public and may be used. The identifier of the patch is aafbd37d381b618312ebdf5ddf57027f62c14fdd. It is suggested to install a patch to address this issue.
The Infineon Airoc Wi-Fi driver's transmit callback airoc_mgmt_send() in drivers/wifi/infineon/airoc_wifi.c allocates a net_buf from the fixed airoc_pool for every outbound packet. When whd_network_send_ethernet_data() returns a synchronous failure, the underlying WHD library does not take ownership of the buffer, but the pre-fix driver returned -EIO without releasing it. Each failed transmit therefore permanently leaks one buffer from the pool. airoc_pool is small and fixed (AIROC_WIFI_TX_PACKET_POOL_COUNT + AIROC_WIFI_RX_PACKET_POOL_COUNT, default 20 buffers) and is shared by WHD's whd_host_buffer_get callback for both transmit and receive. Once enough send failures have leaked the pool dry, airoc_wifi_host_buffer_get() returns WHD_BUFFER_ALLOC_FAIL for all subsequent allocations, so both transmit and the WHD-driven receive path fail and Wi-Fi connectivity is lost until the device is rebooted. The leak occurs only on the transmit error path. A Wi-Fi-adjacent attacker can influence the conditions that cause synchronous send failures (for example by deauthenticating/disassociating the station while the local stack continues to attempt transmits), and ordinary transient failures over the device's lifetime accumulate toward the same state. Reliable on-demand triggering is of high complexity and the impact is availability-only, but the resulting denial of service is permanent and non-recoverable without a reboot. The fix releases the buffer with airoc_wifi_buffer_release() on the failure branch, returning it to the pool. The commit also removes a redundant k_sem_give() in airoc_mgmt_disconnect(); because data->sema_common is a binary semaphore (limit 1) the duplicate give merely saturated at 1 and had no security impact.
In the Linux kernel, the following vulnerability has been resolved: gpio: pca953x: fix pca953x_irq_bus_sync_unlock regmap lock Locking is disabled in the regmap config as this driver uses its own lock. This means that all calls to regmap functions (read or write) must hold the i2c_lock. The function pca953x_irq_bus_sync_unlock() did not do this, and it was therefore possible that multiple threads could cause an incorrect register to be read/written. A previous patch partly fixed this, but only protected the write to the interrupt mask register, and not the read from the direction register.
In the Linux kernel, the following vulnerability has been resolved: drm/amd/display: Check for tg ops in dce110_set_avmute Some older DCE timing generators do not implement is_tg_enabled in their ops table. Calling it unconditionally when waiting for AV mute frames causes a NULL pointer dereference on Southern Islands dGPUs when turning the display off over HDMI. Check that tg and the required ops exist before waiting for frames. (cherry picked from commit 2686a0c0aaa07bec2e24131835cf27b5fd4935a5)
curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'
Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.
Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.